Colin Bristow
Stock Analyst at UBS
(2.39)
# 1,526
Out of 4,479 analysts
65
Total ratings
47.22%
Success rate
-1.16%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $284 → $307 | $310.77 | -1.21% | 5 | May 3, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,090 → $1,099 | $1,044.66 | +5.20% | 1 | Apr 17, 2024 | |
| BIIB Biogen | Maintains: Neutral | $250 → $214 | $228.82 | -6.48% | 9 | Apr 17, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $81 → $75 | $68.40 | +9.65% | 2 | Apr 17, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $498 → $466 | $473.78 | -1.64% | 11 | Apr 17, 2024 | |
| ENGN enGene Holdings | Initiates: Buy | $37 | $8.99 | +311.57% | 1 | Mar 28, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $56 → $54 | $19.78 | +173.00% | 2 | Mar 1, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $164 → $167 | $154.20 | +8.30% | 5 | Mar 1, 2024 | |
| BTAI BioXcel Therapeutics | Downgrades: Neutral | $9 → $4 | $1.12 | +257.14% | 3 | Feb 21, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $135 → $148 | $127.72 | +15.88% | 3 | Feb 2, 2024 | |
| PFE Pfizer | Maintains: Neutral | $34 → $27 | $27.83 | -2.98% | 4 | Dec 14, 2023 | |
| IMVT Immunovant | Maintains: Buy | $55 → $56 | $26.52 | +111.16% | 4 | Dec 1, 2023 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $29 → $27 | $5.72 | +372.03% | 3 | Oct 4, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $428 → $420 | $906.71 | -53.68% | 1 | Dec 15, 2022 | |
| OMER Omeros | Downgrades: Neutral | $12 → $2 | $3.85 | -48.05% | 2 | Dec 8, 2022 | |
| PROK ProKidney | Initiates: Buy | $18 | $2.24 | +703.57% | 1 | Oct 18, 2022 | |
| ABBV AbbVie | Maintains: Neutral | $154 → $146 | $165.96 | -12.03% | 2 | Aug 1, 2022 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $73 → $75 | $40.45 | +85.41% | 1 | Jul 28, 2022 | |
| CCCC C4 Therapeutics | Maintains: Buy | $64 → $26 | $4.52 | +475.22% | 1 | Apr 18, 2022 | |
| CADL Candel Therapeutics | Initiates: Buy | n/a | $6.25 | - | 1 | Aug 23, 2021 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | n/a | $2.27 | - | 1 | Jul 26, 2021 | |
| MTEM Molecular Templates | Initiates: Neutral | n/a | $1.16 | - | 1 | Feb 1, 2021 | |
| PTCT PTC Therapeutics | Initiates: Neutral | n/a | $30.39 | - | 1 | Oct 28, 2020 |
Amgen
May 3, 2024
Maintains: Neutral
Price Target: $284 → $307
Current: $310.77
Upside: -1.21%
Regeneron Pharmaceuticals
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $1,044.66
Upside: +5.20%
Biogen
Apr 17, 2024
Maintains: Neutral
Price Target: $250 → $214
Current: $228.82
Upside: -6.48%
Gilead Sciences
Apr 17, 2024
Maintains: Neutral
Price Target: $81 → $75
Current: $68.40
Upside: +9.65%
Vertex Pharmaceuticals
Apr 17, 2024
Maintains: Buy
Price Target: $498 → $466
Current: $473.78
Upside: -1.64%
enGene Holdings
Mar 28, 2024
Initiates: Buy
Price Target: $37
Current: $8.99
Upside: +311.57%
Rocket Pharmaceuticals
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $19.78
Upside: +173.00%
Sarepta Therapeutics
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $154.20
Upside: +8.30%
BioXcel Therapeutics
Feb 21, 2024
Downgrades: Neutral
Price Target: $9 → $4
Current: $1.12
Upside: +257.14%
Merck & Co.
Feb 2, 2024
Maintains: Buy
Price Target: $135 → $148
Current: $127.72
Upside: +15.88%
Pfizer
Dec 14, 2023
Maintains: Neutral
Price Target: $34 → $27
Current: $27.83
Upside: -2.98%
Immunovant
Dec 1, 2023
Maintains: Buy
Price Target: $55 → $56
Current: $26.52
Upside: +111.16%
ALX Oncology Holdings
Oct 4, 2023
Maintains: Buy
Price Target: $29 → $27
Current: $5.72
Upside: +372.03%
Eli Lilly
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $906.71
Upside: -53.68%
Omeros
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.85
Upside: -48.05%
ProKidney
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.24
Upside: +703.57%
AbbVie
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $165.96
Upside: -12.03%
Bristol-Myers Squibb Company
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $40.45
Upside: +85.41%
C4 Therapeutics
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $4.52
Upside: +475.22%
Candel Therapeutics
Aug 23, 2021
Initiates: Buy
Price Target: n/a
Current: $6.25
Upside: -
Acumen Pharmaceuticals
Jul 26, 2021
Initiates: Buy
Price Target: n/a
Current: $2.27
Upside: -
Molecular Templates
Feb 1, 2021
Initiates: Neutral
Price Target: n/a
Current: $1.16
Upside: -
PTC Therapeutics
Oct 28, 2020
Initiates: Neutral
Price Target: n/a
Current: $30.39
Upside: -